At a glance
- Originator National Cancer Center (Tokyo); Taiho Pharmaceutical; Teikyo University
- Class Pyrimidine nucleosides; Small molecules
- Mechanism of Action Nucleoside transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 Mar 2007 Discontinued - Preclinical for Solid tumours in Japan (unspecified route)
- 20 Jun 2001 No-Development-Reported for Solid tumours in Japan (Unknown route)
- 10 Jul 1996 Preclinical development for Solid tumours in Japan (Unknown route)